| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 137, 7-12, Copyright © 1990 by American Society for Investigative Pathology
REGULAR ARTICLES |
L Bell and JA Madri
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, CT 06510.
The blood vessel wall's response to injury is an important determinant of luminal size and vessel function. The physiologic migration of endothelial cells from the edges of a wound and the pathophysiologic migration of medial smooth muscle cells into the intima are two important components of the vessel wall's response to injury. The influence of the angiotensin system on endothelial and smooth muscle cell migration have not been examined. In the present study, the influence of angiotensin system components on bovine aortic endothelial cell (BAEC) and bovine aortic smooth muscle cell (BASMC) migration after release of cultured cell monolayers from contact inhibition was determined. The angiotensin-converting enzyme (ACE) inhibitor lisinopril increased BAEC migration 41% +/- 3% (P less than 0.001), as did the specific angiotensin II antagonist sar1, ile8-angiotensin II (SAR) (41% +/- 3% (P less than 0.001). Exogenous angiotensin I and angiotensin II did not affect BAEC migration. Exogenous angiotensin II abolished the effect of lisinopril on BAEC migration. Lisinopril increased cell-associated u-plasminogen activator (u-PA) 23% +/- 3% (P less than 0.001) in migrating BAEC and angiotensin II abolished this increase. SAR increased u-PA 33% +/- 0% (P less than 0.001). In contrast, these agents had the opposite effect on smooth muscle cells. Angiotensin II increased smooth muscle cell migration 40% +/- 3% (P less than 0.001), and this effect was abolished by SAR. Angiotensin II also increased cell-associated u-PA 83% +/- 7% (P less than 0.001) in migrating BASMC. The increase in BAEC migration with inhibition of endothelial cell angiotensin II stimulation, either with lisinopril or SAR, also was associated with an increase in cell-associated u-PA. These results indicate that lisinopril interrupts an autocrine pathway in endothelial cells, in which endothelial cell-derived angiotensin I is converted to angiotensin II by ACE, and imply that angiotensin- converting enzyme inhibitors in vivo would act to reduce vessel wall injury by directly increasing the rate of endothelial cell wound closure; by increasing the antithrombotic tendency of the endothelium via enhanced u-PA; and indirectly, by decreasing production of angiotensin II and thereby the rate of smooth muscle cell migration into the intima.
This article has been cited by other articles:
 |
|
 |
|
  S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Gerthoffer Mechanisms of Vascular Smooth Muscle Cell Migration Circ. Res., March 16, 2007; 100(5): 607 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ohtani, K. Egashira, Y. Ihara, K. Nakano, K. Funakoshi, G. Zhao, M. Sata, and K. Sunagawa Angiotensin II Type 1 Receptor Blockade Attenuates In-Stent Restenosis by Inhibiting Inflammation and Progenitor Cells Hypertension, October 1, 2006; 48(4): 664 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ushio-Fukai Redox signaling in angiogenesis: Role of NADPH oxidase Cardiovasc Res, July 15, 2006; 71(2): 226 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fujita, I. Hayashi, S. Yamashina, A. Fukamizu, M. Itoman, and M. Majima Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth Carcinogenesis, February 1, 2005; 26(2): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Benndorf, R. H. Boger, S. Ergun, A. Steenpass, and T. Wieland Angiotensin II Type 2 Receptor Inhibits Vascular Endothelial Growth Factor-Induced Migration and In Vitro Tube Formation of Human Endothelial Cells Circ. Res., September 5, 2003; 93(5): 438 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Desideri, M. C. Bravi, M. Tucci, G. Croce, M. C. Marinucci, A. Santucci, E. Alesse, and C. Ferri Angiotensin II Inhibits Endothelial Cell Motility Through an AT1-Dependent Oxidant-Sensitive Decrement of Nitric Oxide Availability Arterioscler. Thromb. Vasc. Biol., July 1, 2003; 23(7): 1218 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Baumbach, C. D. Sigmund, and F. M. Faraci Cerebral Arteriolar Structure in Mice Overexpressing Human Renin and Angiotensinogen Hypertension, January 1, 2003; 41(1): 50 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Katada, M. Muramatsu, I. Hayashi, M. Tsutsumi, Y. Konishi, and M. Majima Significance of Vascular Endothelial Cell Growth Factor Up-Regulation Mediated via a Chymase-Angiotensin-Dependent Pathway during Angiogenesis in Hamster Sponge Granulomas J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 949 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. NORIS, N. AZZOLLINI, A. PEZZOTTA, M. MISTER, A. BENIGNI, G. MARCHETTI, E. GAGLIARDINI, N. PERICO, and G. REMUZZI Combined Treatment with Mycophenolate Mofetil and an Angiotensin II Receptor Antagonist Fully Protects from Chronic Rejection in a Rat Model of Renal Allograft J. Am. Soc. Nephrol., September 1, 2001; 12(9): 1937 - 1946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Niebauer, P. S Tsao, P. S Lin, R. E Pratt, and J. P Cooke Cholesterol-induced upregulation of angiotensin II and its effects on monocyte-endothelial interaction and superoxide production Vascular Medicine, August 1, 2001; 6(3): 133 - 138. [Abstract] [PDF]
|
|
|
|
|
|
C. D. Kim, H. H. Kim, Y. K. Kim, Y. K. Kwak, S.-O. Kim, S.-E. Yoo, and K. W. Hong Antiangiogenic Effect of KR31372 in Rat Sponge Implant Model J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1085 - 1090. [Abstract] [Full Text]
|
|
|
|
 |
|
 K.E. Rodgers, S. Xiong, R. Steer, and G.S. diZerega Effect of Angiotensin II on Hematopoietic Progenitor Cell Proliferation Stem Cells, July 1, 2000; 18(4): 287 - 294. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Muntwyler and T.F. Luscher Assessment of cardiovascular risk: time to apply genetic risk factors? Eur. Heart J., April 2, 2000; 21(8): 611 - 613. [PDF]
|
|
|
|
 |
|
 M. Muramatsu, J. Katada, I. Hayashi, and M. Majima Chymase as a Proangiogenic Factor. A POSSIBLE INVOLVEMENT OF CHYMASE-ANGIOTENSIN-DEPENDENT PATHWAY IN THE HAMSTER SPONGE ANGIOGENESIS MODEL J. Biol. Chem., February 25, 2000; 275(8): 5545 - 5552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Uehara, H. Urata, M. Sasaguri, M. Ideishi, N. Sakata, T. Tashiro, M. Kimura, and K. Arakawa Increased Chymase Activity in Internal Thoracic Artery of Patients With Hypercholesterolemia Hypertension, January 1, 2000; 35(1): 55 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takeda, T. Ichiki, Y. Funakoshi, K. Ito, and A. Takeshita Downregulation of Angiotensin II Type 1 Receptor by All-trans Retinoic Acid in Vascular Smooth Muscle Cells Hypertension, January 1, 2000; 35(1): 297 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Okamura, M. Ohishi, H. Rakugi, T. Katsuya, Y. Yanagitani, S. Takiuchi, Y. Taniyama, K. Moriguchi, H. Ito, Y. Higashino, et al. Pharmacogenetic Analysis of the Effect of Angiotensin-Converting Enzyme Inhibitor on Restenosis After Percutaneous Transluminal Coronary Angioplasty Angiology, October 1, 1999; 50(10): 811 - 822. [Abstract] [PDF]
|
|
|
|
|
|
N. de las Heras, P. Aragoncillo, R. Maeso, S. Vazquez-Perez, J. Navarro-Cid, M. DeGasparo, J. Mann, L. M. Ruilope, V. Cachofeiro, and V. Lahera AT1 Receptor Antagonism Reduces Endothelial Dysfunction and Intimal Thickening in Atherosclerotic Rabbits Hypertension, October 1, 1999; 34(4): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ihara, H. Urata, A. Kinoshita, J. Suzumiya, M. Sasaguri, M. Kikuchi, M. Ideishi, and K. Arakawa Increased Chymase-Dependent Angiotensin II Formation in Human Atherosclerotic Aorta Hypertension, June 1, 1999; 33(6): 1399 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Brown and D. E. Vaughan Angiotensin-Converting Enzyme Inhibitors Circulation, April 14, 1998; 97(14): 1411 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Belle, C. Bauters, T. Asahara, and J. M. Isner Endothelial regrowth after arterial injury: from vascular repair to therapeutics Cardiovasc Res, April 1, 1998; 38(1): 54 - 68. [Full Text] [PDF]
|
|
|
|
|
|
M. Ohishi, M. Ueda, H. Rakugi, A. Okamura, T. Naruko, A. E. Becker, K. Hiwada, A. Kamitani, K. Kamide, J. Higaki, et al. Upregulation of Angiotensin-Converting Enzyme During the Healing Process After Injury at the Site of Percutaneous Transluminal Coronary Angioplasty in Humans Circulation, November 18, 1997; 96(10): 3328 - 3337. [Abstract] [Full Text]
|
|
|
|
|
|
M. S. Fernandez-Alfonso, P. A. Martorana, I. Licka, P. van Even, D. Trobisch, B. A. Scholkens, and M. Paul Early Induction of Angiotensin I–Converting Enzyme in Rat Carotid Artery After Balloon Injury Hypertension, August 1, 1997; 30(2): 272 - 277. [Abstract] [Full Text]
|
|
|
|
|
|
G. Liu, E. Espinosa, B. S. Oemar, and T. F. Luscher Bimodal Effects of Angiotensin II on Migration of Human and Rat Smooth Muscle Cells : Direct Stimulation and Indirect Inhibition Via Transforming Growth Factor-ß1 Arterioscler. Thromb. Vasc. Biol., July 1, 1997; 17(7): 1251 - 1257. [Abstract] [Full Text]
|
|
|
|
|
|
M. Kohno, K. Yokokawa, H. Kano, K. Yasunari, M. Minami, T. Hanehira, and J. Yoshikawa Adrenomedullin Is a Potent Inhibitor of Angiotensin II–Induced Migration of Human Coronary Artery Smooth Muscle Cells Hypertension, June 1, 1997; 29(6): 1309 - 1313. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. K. Berfield, D. Spicer, and C. K. Abrass Insulin-like Growth Factor I (IGF-I) Induces Unique Effects in the Cytoskeleton of Cultured Rat Glomerular Mesangial Cells J. Histochem. Cytochem., April 1, 1997; 45(4): 583 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Diet, R. E. Pratt, G. J. Berry, N. Momose, G. H. Gibbons, and V. J. Dzau Increased Accumulation of Tissue ACE in Human Atherosclerotic Coronary Artery Disease Circulation, December 1, 1996; 94(11): 2756 - 2767. [Abstract] [Full Text]
|
|
|
|
|
|
A. Papapetropoulos, A. Antonov, R. Virmani, F. D. Kolodgie, D. H. Munn, N. Marczin, J. W. Ryan, R. G. Gerrity, and J. D. Catravas Monocyte- and Cytokine-Induced Downregulation of Angiotensin-Converting Enzyme in Cultured Human and Porcine Endothelial Cells Circ. Res., September 1, 1996; 79(3): 512 - 523. [Abstract] [Full Text]
|
|
|
|
|
|
W. R. Huckle, M. D. Drag, W. R. Acker, M. Powers, R. C. McFall, D. J. Holder, T. Fujita, I. I. Stabilito, D. Kim, D. L. Ondeyka, et al. Effects of Subtype-Selective and Balanced Angiotensin II Receptor Antagonists in a Porcine Coronary Artery Model of Vascular Restenosis Circulation, March 1, 1996; 93(5): 1009 - 1019. [Abstract] [Full Text]
|
|
|
|
|
|
R. Brandl, P. C. Maurer, B. Hofling, and G. Bauriedel Migration Behavior of Human Smooth Muscle Cells Cultivated from Restenotic and Primary Lesions Angiology, November 1, 1995; 46(11): 973 - 980. [Abstract] [PDF]
|
|
|
|
 |
|
 H.-P. Hartung, J. J. Archelos, J. Zielasek, R. Gold, M. Koltzenburg, K.-H. Reiners, and K. V. Toyka Circulating adhesion molecules and inflammatory mediators in demyelination: A review Neurology, June 1, 1995; 45(6_Suppl_6): S22 - S32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Noda-Heiny, A. Daugherty, and B. E. Sobel Augmented Urokinase Receptor Expression in Atheroma Arterioscler. Thromb. Vasc. Biol., January 1, 1995; 15(1): 37 - 43. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Chassagne, C. Adamy, P. Ratajczak, B. Gingras, E. Teiger, E. Planus, P. Oliviero, L. Rappaport, J.-L. Samuel, and S. Meloche Angiotensin II AT2 receptor inhibits smooth muscle cell migration via fibronectin cell production and binding Am J Physiol Cell Physiol, April 1, 2002; 282(4): C654 - C664. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
